Literature DB >> 3495702

Androgen receptor predominance in human ovarian carcinoma.

R Kühnel, J de Graaff, B R Rao, J G Stolk.   

Abstract

Cytosols of 94 untreated common epithelial ovarian cancer tissues were analysed for the presence of estrogen-, progesterone- and androgen receptors. Androgen receptors clearly predominated (90%) over and above estrogen- (55%) and progesterone receptors (52%). Further characterisation particularly of the androgen receptor revealed steroid-receptor complex with the sedimentation coefficient similar to ovalbumin (3,6 S). Only androgens, natural and synthetic, were able to alter the sedimentation profile. Estrogen appeared to slightly lower the peak, while progesterone and cortisol did not alter the profile at all. No difference in receptor concentrations between tumor tissues from pre-, peri- and postmenopausal women was found. The serum hormone levels (estradiol-17 beta, testosterone, FSH, LH) measured preoperatively in 20 postmenopausal patients did not correlate with the receptor status. Majority of the ovarian carcinomas studied contained androgen receptors. We therefore suggest consideration of the addition of anti-androgens to the therapeutic strategies applicable to ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495702     DOI: 10.1016/0022-4731(87)90106-3

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  17 in total

1.  Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses.

Authors:  H C van Doorn; C W Burger; P van der Valk; H M Bonfrèr
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

2.  Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk.

Authors:  Kathryn L Terry; Immaculata De Vivo; Linda Titus-Ernstoff; Mei-Chiung Shih; Daniel W Cramer
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

3.  Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer.

Authors:  Brian Y Park; Rachel N Grisham; Bjørnar den Hollander; Dharmarao Thapi; Tara Berman; Elisa de Stanchina; Qin Zhou; Gopa Iyer; Carol Aghajanian; David R Spriggs
Journal:  Cancer Invest       Date:  2016-11-08       Impact factor: 2.176

4.  Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.

Authors:  Beryl L Manning-Geist; Sushmita B Gordhandas; Dilip D Giri; Alexia Iasonos; Qin Zhou; Jeffrey Girshman; Roisin E O'Cearbhaill; Dmitriy Zamarin; Stuart M Lichtman; Paul J Sabbatini; William P Tew; Karen Li; Autumn S McDonnell; Emeline M Aviki; Dennis S Chi; Carol A Aghajanian; Rachel N Grisham
Journal:  Gynecol Oncol       Date:  2021-11-08       Impact factor: 5.304

5.  Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States).

Authors:  A I Adler; N S Weiss; M L Kamb; J L Lyon
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

Review 6.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

7.  Radiolabeled 5-iodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine and its 5'-monophosphate for imaging and therapy of androgen receptor-positive cancers: synthesis and biological evaluation.

Authors:  Zbigniew P Kortylewicz; Jessica Nearman; Janina Baranowska-Kortylewicz
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

8.  Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression.

Authors:  Fengkun Du; Yan Li; Wensheng Zhang; Shubha P Kale; Harris McFerrin; Ian Davenport; Guangdi Wang; Elena Skripnikova; Xiao-Lin Li; Nathan J Bowen; Leticia B McDaniels; Yuan-Xiang Meng; Paula Polk; Yong-Yu Liu; Qian-Jin Zhang
Journal:  Tumour Biol       Date:  2016-03-02

9.  Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary.

Authors:  Vinod B Shidham; Richard A Komorowski; Jinobya K Machhi
Journal:  Diagn Pathol       Date:  2006-10-04       Impact factor: 2.644

10.  Androgen-related expression of G-proteins in ovarian cancer.

Authors:  L A Sheach; E M Adeney; A Kucukmetin; S J Wilkinson; A D Fisher; A Elattar; C N Robson; R J Edmondson
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.